Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer

The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHENG WEIJI, BAI YA, PU JIANGNI, LUO GUANCONG, CHAI YAN, XU TIANRUI, ANJU
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ZHENG WEIJI BAI YA PU JIANGNI LUO GUANCONG CHAI YAN XU TIANRUI ANJU
description	The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit cell proliferation of EGFR mutant non-small cell lung cancer, the Gefitinib and Fubatinib have a synergistic effect in the aspect of resisting cell proliferation of EGFR mutant non-small cell lung cancer, and the application of Gefitinib and Fubatinib in preparation of drugs for treating EGFR mutant non-small cell lung cancer can be used for preparing drugs for treating EGFR mutant non-small cell lung cancer in preparation of drugs for treating EGFR mutant non-small cell lung cancer. Meanwhile, the drug resistance of non-small cell lung cancer cells to Gefitinib can be reversed, the sensitivity of the Gefitinib drug-resistant non-small cell lung cancer cells to Gefitinib can be enhanced, activation of pAKT, pERK an
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN118453618A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN118453618A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN118453618A3</originalsourceid><addsrcrecordid>eNqNy7EKwkAQBNA0FqL-w-YDUoSopA1BsbKyD5vNXly47B13J_6-J4q1zQwMb9ZF7Ly3QpjEKTgDMxtJojICuWUU5Qmeku5g3IifXRR8YI_h91l4Eso0owAp8BvOoE6ruKC1QJzDPvJGqMRhW6wM2si7b2-K8ny69ZeKvRs4eiRWTkN_ret2f2iOdds1_5gXQYpEcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer</title><source>esp@cenet</source><creator>ZHENG WEIJI ; BAI YA ; PU JIANGNI ; LUO GUANCONG ; CHAI YAN ; XU TIANRUI ; ANJU</creator><creatorcontrib>ZHENG WEIJI ; BAI YA ; PU JIANGNI ; LUO GUANCONG ; CHAI YAN ; XU TIANRUI ; ANJU</creatorcontrib><description>The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit cell proliferation of EGFR mutant non-small cell lung cancer, the Gefitinib and Fubatinib have a synergistic effect in the aspect of resisting cell proliferation of EGFR mutant non-small cell lung cancer, and the application of Gefitinib and Fubatinib in preparation of drugs for treating EGFR mutant non-small cell lung cancer can be used for preparing drugs for treating EGFR mutant non-small cell lung cancer in preparation of drugs for treating EGFR mutant non-small cell lung cancer. Meanwhile, the drug resistance of non-small cell lung cancer cells to Gefitinib can be reversed, the sensitivity of the Gefitinib drug-resistant non-small cell lung cancer cells to Gefitinib can be enhanced, activation of pAKT, pERK an</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240809&DB=EPODOC&CC=CN&NR=118453618A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240809&DB=EPODOC&CC=CN&NR=118453618A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHENG WEIJI</creatorcontrib><creatorcontrib>BAI YA</creatorcontrib><creatorcontrib>PU JIANGNI</creatorcontrib><creatorcontrib>LUO GUANCONG</creatorcontrib><creatorcontrib>CHAI YAN</creatorcontrib><creatorcontrib>XU TIANRUI</creatorcontrib><creatorcontrib>ANJU</creatorcontrib><title>Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer</title><description>The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit cell proliferation of EGFR mutant non-small cell lung cancer, the Gefitinib and Fubatinib have a synergistic effect in the aspect of resisting cell proliferation of EGFR mutant non-small cell lung cancer, and the application of Gefitinib and Fubatinib in preparation of drugs for treating EGFR mutant non-small cell lung cancer can be used for preparing drugs for treating EGFR mutant non-small cell lung cancer in preparation of drugs for treating EGFR mutant non-small cell lung cancer. Meanwhile, the drug resistance of non-small cell lung cancer cells to Gefitinib can be reversed, the sensitivity of the Gefitinib drug-resistant non-small cell lung cancer cells to Gefitinib can be enhanced, activation of pAKT, pERK an</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNy7EKwkAQBNA0FqL-w-YDUoSopA1BsbKyD5vNXly47B13J_6-J4q1zQwMb9ZF7Ly3QpjEKTgDMxtJojICuWUU5Qmeku5g3IifXRR8YI_h91l4Eso0owAp8BvOoE6ruKC1QJzDPvJGqMRhW6wM2si7b2-K8ny69ZeKvRs4eiRWTkN_ret2f2iOdds1_5gXQYpEcA</recordid><startdate>20240809</startdate><enddate>20240809</enddate><creator>ZHENG WEIJI</creator><creator>BAI YA</creator><creator>PU JIANGNI</creator><creator>LUO GUANCONG</creator><creator>CHAI YAN</creator><creator>XU TIANRUI</creator><creator>ANJU</creator><scope>EVB</scope></search><sort><creationdate>20240809</creationdate><title>Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer</title><author>ZHENG WEIJI ; BAI YA ; PU JIANGNI ; LUO GUANCONG ; CHAI YAN ; XU TIANRUI ; ANJU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN118453618A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHENG WEIJI</creatorcontrib><creatorcontrib>BAI YA</creatorcontrib><creatorcontrib>PU JIANGNI</creatorcontrib><creatorcontrib>LUO GUANCONG</creatorcontrib><creatorcontrib>CHAI YAN</creatorcontrib><creatorcontrib>XU TIANRUI</creatorcontrib><creatorcontrib>ANJU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHENG WEIJI</au><au>BAI YA</au><au>PU JIANGNI</au><au>LUO GUANCONG</au><au>CHAI YAN</au><au>XU TIANRUI</au><au>ANJU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer</title><date>2024-08-09</date><risdate>2024</risdate><abstract>The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit cell proliferation of EGFR mutant non-small cell lung cancer, the Gefitinib and Fubatinib have a synergistic effect in the aspect of resisting cell proliferation of EGFR mutant non-small cell lung cancer, and the application of Gefitinib and Fubatinib in preparation of drugs for treating EGFR mutant non-small cell lung cancer can be used for preparing drugs for treating EGFR mutant non-small cell lung cancer in preparation of drugs for treating EGFR mutant non-small cell lung cancer. Meanwhile, the drug resistance of non-small cell lung cancer cells to Gefitinib can be reversed, the sensitivity of the Gefitinib drug-resistant non-small cell lung cancer cells to Gefitinib can be enhanced, activation of pAKT, pERK an</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	chi ; eng
recordid	cdi_epo_espacenet_CN118453618A
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A24%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHENG%20WEIJI&rft.date=2024-08-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN118453618A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true